Rocket Pharma may look like an early-stage biotech, but it already has a proven way to make and scale its gene therapies in-house—something the market often overlooks. A big upcoming clinical readout could confirm a second technology platform and force investors to rethink what this business is worth.Read more

Akebia’s Vafseo aims to replace the hassle of anemia shots in kidney disease with a pill that helps the body make its own blood-building signal and use iron better. The big swing isn’t just the science—it’s whether the largest dialysis chains decide to bake it into their standard treatment plans, quickly opening the door to many more patients.Read more

Mustang Bio trades as if its drug pipeline is worthless, even though it still has meaningful cash on hand and early cancer results that include a rare long-lasting complete response. The next few months could be pivotal as a new hospital-led study is expected to restart dosing, but a looming exchange listing deadline could force a share change that adds pressure.Read more

A new needle-free option for severe allergy treatment starts to break the long-standing grip of the familiar injector, and the market treats it like a losing fight between two newcomers. The more interesting angle is that both newcomers could grow the whole category by winning over people who avoid needles—if they can navigate insurance gatekeepers and a fast-approaching head‑to‑head launch.Read more

The market treats InMode like its best days are behind it, even though it still sits on a large cash pile and continues to generate cash from its devices. If investor sentiment turns and new uses like eye care and men’s wellness gain traction, the stock could look very differently—while a big cash cushion and buybacks may limit how bad things can get.Read more

The Hidden Bottleneck in Drug Development: Why Charles River Acquired a Cambodian Primate Supplier On January 12, 2026, Charles River Laboratories announced that it had signed an agreement to acquire the assets of K.F. (Cambodia) Ltd., a major non-human primate (NHP) breeding and supply company. [$510M] At first glance, this transaction might appear to be a routine supply chain acquisition in the contract research organization (CRO) industry.Read more

Dear Inotiv, My name is Jong Ik Kwon, DVM , a graduate of Seoul National University College of Veterinary Medicine. Earlier in my career, I worked for Kwangdong Pharmaceutical as a Clinical Research Manager (CRM) for two years , where I gained direct experience in clinical development, regulatory processes, and pharmaceutical operations.Read more